It now seems providential that the World Health Organization named 2020 the Year of the Nurse and Midwife to honor Florence Nightingale’s 200th birthday. Who could have predicted how the world would rely on nurses to change the course of the COVID-19 coronavirus pandemic by upholding Nightingale’s leadership and principles of infection control from the 19th century?
COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.
On April 29, 2020, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
While the world is in the throes of the COVID-19 coronavirus pandemic, cancer research marshals forward with a focus on CAR T-cell therapy.
As the world embarks on unprecedented research efforts to prevent and treat the COVID-19 coronavirus, patients with cancer and healthcare providers alike may be interested in using herbal products to boost their immune system or relieve anxiety and stress. However, finding accurate information is challenging: no herbs have been scientifically proven to prevent or treat COVID-19, and some may even cause harm.
From international guidelines to economic stimulus and legislative support, the COVID-19 coronavirus pandemic is now global leaders’ top priority.
Daratumumab (Darzalex®) was originally approved by the U.S. Food and Drug Administration in 2015 with additional indications added since. The most recent new indication was approved in September 2019 for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplantation. In May 2020, daratumumab and hyaluronidase-fihj (Darzalex Faspro™), a subcutaneous (SQ) formulation, was approved.
On April 1, 2020, the U.S. House of Representatives Subcommittee on Economic and Consumer Policy asked the U.S. Food and Drug Administration (FDA) to clear the market of e-cigarettes because of the COVID-19 coronavirus pandemic. It was responding to FDA’s request to give e-cigarette manufacturers four additional months to submit applications to stay on the market before enforcing a ban.
Healthcare providers still lack sufficient personal protective equipment (PPE) to safely treat patients with COVID-19 coronavirus. Citing insufficient federal coordination, members of Congress urged the Trump administration follow through on implementing the $16 million PPE funding provided in the Coronavirus Aid, Relief, and Economic Security (CARES) Act.